Species-Independent Complement Activation Measurement
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for measuring complement activation in animals are limited, with available assays being narrower in scope, less sensitive, and difficult to standardize, particularly for species other than humans, and often rely on hemolytic reactions that are hard to quantify accurately.
Innovation Solution
A species-independent assay using human C split products as surrogate markers, specifically employing a C3 or C4 specificity converting protein matrix to measure animal C3 and C4 levels by incubating animal specimens with human C-depleted serum and activators like zymosan, allowing for the quantitation of C activation through ELISA kits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If hemolytic reactions are used to measure complement activation in animals, then the measurement can be performed across multiple species, but the quantification accuracy becomes difficult to standardize
Solution Approach 1:
The patent introduces a human C3 or C4 specificity converting protein matrix as an intermediary substance. This matrix contains human C3 or C4 proteins that convert animal complement activation into the formation of human C3a, C4a, C5a, or SC5b-9 split products. These human split products serve as measurable intermediaries that can be quantified using standardized human ELISA kits, thereby enabling accurate cross-species measurement while maintaining standardization.
Solution Approach 2:
The patent changes the measurement parameter from direct animal complement split products (which are species-specific and hard to standardize) to human complement split products (which have standardized ELISA assays). By incubating animal specimens with human C-depleted serum and activators, the system transforms the measurement into detecting human C3a, C4a, C5a, or SC5b-9 levels, which have well-established quantification methods.
2Measurement precision
If species-specific assays are used for each animal, then measurement precision can be maintained, but the device complexity and number of required assays increase
Solution Approach 1:
The patent creates a universal assay system where a single human C3 or C4 specificity converting protein matrix can measure complement activation across multiple animal species. Instead of requiring separate species-specific assays, this universal matrix works with specimens from any species by converting their complement activation into detectable human split products, thereby reducing the number of different assays needed while maintaining measurement accuracy.
3Reliability
If existing complement activation assays are used in animals, then the basic functionality can be assessed, but the sensitivity and scope are limited
Solution Approach 1:
The human C3 or C4 specificity converting protein matrix acts as an amplifier and translator. It takes the animal's complement activation signal and converts it into human split products that can be detected with high sensitivity using commercial ELISA kits. This intermediary system expands the detection sensitivity beyond what is achievable with direct animal complement measurement.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables precise, pan-species measurement of complement activation in various animals, overcoming the limitations of existing assays by providing a standardized and sensitive method for assessing C activation levels, applicable across different species.
Implementation Method 1
The C3 convertase is a multiprotein complexes that assembles upon C activation, and converts C3 to C3a and C3b
Implementation Method 2
determining the production of one or more human proteins by ELISA or other analytical methods
Data Source
AI summary
A method for species-independent measurement of complement (C) activation in animals. The method comprises taking samples in the range of 3-100 microliter of anticoagulated blood, plasma or serum of an animal (specimen), mixing the specimen with a specificity converting protein matrix (SCM), mixing to the specimen/SCM mixture an activator of the C system (Act), incubating the specimen/SCM/Act mixture at a temperature between 36° C. to 38° C. for a time of 5-120 min and determining the production of one or more human proteins by ELISA or other analytical methods.